神経障害治療薬の世界市場：現状分析・予測（2022年～2028年）

世界の神経障害治療薬の市場規模は、予測期間中に約5％の著しい成長率で推移すると予測されています。

熟練した医療従事者の存在や、治療時の安全性と有効性から、市場は最も速い成長率を示すと予想されています。脳動脈瘤、動静脈奇形などの神経血管疾患を患う患者の増加も、市場の成長に寄与しています。

当レポートでは、世界の神経障害治療薬市場について調査し、収益、疾患・薬物クラス・流通チャネル・地域別の市場洞察、市場力学、機会、動向、企業プロファイル等に関する情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目的
• ステークホルダー
• 制限

第2章 調査手法または前提条件

• 神経障害治療薬市場の調査プロセス
• 神経障害治療薬市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 神経障害治療薬市場におけるCOVID-19の影響

第6章 神経障害治療薬市場の収益（10億米ドル）、2020年～2028年F

第7章 市場洞察：疾患別

• 神経血管疾患
• 中枢神経系外傷
• 神経変性疾患
• 感染症
• 中枢神経系がん
• その他

第8章 市場洞察：薬物クラス別

• 鎮痛薬
• 麻酔薬
• 抗けいれん薬
• 抗てんかん薬
• 抗パーキンソン病薬
• その他

第9章 市場洞察：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他の地域

第11章 神経障害治療薬：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第12章 神経障害治療薬市場：機会

第13章 神経障害治療薬市場：動向

第14章 需要側・供給側分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業プロファイル

• AbbVie Inc.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Merck KGaA

第18章 免責事項

The global neurologic disorders therapeutics Market is expected to grow at a significant rate of around 5% during the forecast period. Neurologic disorder is a disorder of the nervous system. As per various studies, the growth of these neurological disorders is spreading rapidly across the world and becoming increasingly common, especially neurodegenerative diseases. Furthermore, Neurologic disorders therapeutics is expected to have the fastest growth rate in the market mainly due to the availability of skilled healthcare professionals, and the safety & efficacy during the treatment procedures. Moreover, the growing patient pool suffering from neurovascular diseases such as brain aneurysms, and arteriovenous malformations are also contributing to the growth of this market during the forecast period. For instance, according to the Brain Aneurysms Foundation, about 30,000 people in the United States suffer a brain aneurysm rupture each year.

AbbVie Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst disease type, neurodegenerative diseases category to witness robust CAGR during the forecast period"

Based on disease type, the market is segmented into neurovascular diseases, CNS trauma, neurodegenerative diseases, infectious diseases, CNS cancer, and others. The neurodegenerative diseases category is to witness considerable growth during the forecast period. This is mainly due to the increasing brain injuries, cerebral disorders, and rising prevalence of hypertension in the geriatric population are the major factors for the growth of the neurologic disorder's therapeutics market during the forecast period. For instance, according to the Brain Aneurysm Foundation, an estimated 6 million Americans are affected by cerebral aneurysms.

"Amongst drug class, the antiepileptics to hold a significant share in the market in 2020"

On the basis of drug class, the market is categorized into analgesics, anesthetics, anticonvulsants, antiepileptics, antiparkinson agents, and others. Among these, the antiepileptics category is to witness significant growth during the forecast period. This is mainly due to these drugs prevent seizures, either by decreasing excitation or enhancing inhibition. Moreover, the growing prevalence of epilepsy demanding for therapeutically effective medications is creating pressure among the market players to introduce AEDs. For instance, in January 2020, Eisai Co. Ltd. announced the launch of FYCOMPA in China for the treatment of partial-onset seizures in patients aged 12 years and older.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the neurologic disorders therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is expected to witness significant growth in the market owing to the availability of market players in the region and the rising initiative undertaken by key players to develop various therapies for different neurological disorders are the major factors that are expected to increase the market share. Moreover, the growing cases of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer's, Parkinson's disease, and brain cancer is fueling the demand for neurologic disorders therapeutics in the region. For instance, around 70,800 people in the United States are diagnosed with brain cancer every year, which represents 1.4% of the total cancer incidence and causes about 2.4% of all cancer deaths in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

The global neurologic disorders therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neurologic Disorders Therapeutics Market
• 2.2. Research Methodology of the Neurologic Disorders Therapeutics Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROLOGIC DISORDERS THERAPEUTICS MARKET

6 NEUROLOGIC DISORDERS THERAPEUTICS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DISEASES

• 7.1. Neurovascular Diseases
• 7.2. CNS Trauma
• 7.3. Neurodegenerative Diseases
• 7.4. Infectious Diseases
• 7.5. CNS Cancer
• 7.6. Others

8 MARKET INSIGHTS BY DRUG CLASS

• 8.1. Analgesics
• 8.2. Anesthetics
• 8.3. Anticonvulsants
• 8.4. Antiepileptics
• 8.5. Anti-Parkinson Agents
• 8.6. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROLOGIC DISORDERS THERAPEUTICS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROLOGIC DISORDERS THERAPEUTICS MARKET OPPORTUNITIES

13 NEUROLOGIC DISORDERS THERAPEUTICS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Five Forces Analysis

17 COMPANY PROFILED

• 17.1. AbbVie Inc.
• 17.2. F. Hoffmann La Roche Ltd.
• 17.3. GlaxoSmithKline Plc
• 17.4. Johnson and Johnson
• 17.5. Mylan NV
• 17.6. Novartis AG
• 17.7. Pfizer Inc.
• 17.8. Sanofi
• 17.9. Teva Pharmaceutical Industries Ltd.
• 17.10. Merck KGaA

18 DISCLAIMER